Zimmer Biomet Holdings, Inc. (NYSE: ZBH): Corporate Profile & Financials
By Raveendran | Updated on: October 24, 2026
Source: Zimmer Biomet Holdings, Inc. Form 10-K & Annual Report For the Year Ended December 31, 2025
Table of Contents
- 1. Quick Facts / Company Snapshot
- 2. Company Overview
- 3. Business Segments
- 4. History and Evolution
- 5. Products and Services
- 6. Brand Portfolio
- 7. Geographical Presence
- 8. Board of Directors and Leadership Team
- 9. Future Strategy
- 10. Key Strengths
- 11. Key Challenges and Risks
- 12. Conclusion and Strategic Outlook
- 13. Official Site
- 14. Income Statement / Profit and loss
- 15. Balance sheet
- 16. Cash flow
- 17. Subsidiaries & Joint Ventures
- 18. Other Investments & Holdings
- 19. Physical properties
- 20. Investments and capital expenditure
- 21. Shareholding pattern / Ownership
- 22. Frequently Asked Questions
Quick Facts / Company Snapshot
| Data Point | Details |
|---|---|
| Company Name | Zimmer Biomet Holdings, Inc. |
| Stock Ticker / Exchanges | (NYSE: ZBH), SIX Swiss Exchange: ZBH |
| Corporate Headquarters | Warsaw, Indiana, United States |
| Chairman, President and CEO | Ivan Tornos |
| Global Workforce | Approximately 17,000 employees |
| Global Presence | Sales in over 100 countries; facilities in more than 45 countries |
| Consolidated Net Sales (2025) | $8,231.5 million |
| Consolidated Net Earnings (2025) | $705.1 million |
| Reportable Operating Segments | Americas, EMEA, Asia Pacific |
Company Overview
Zimmer Biomet Holdings, Inc. is a global medical technology leader operating across the musculoskeletal healthcare space. The company designs, manufactures, and markets orthopedic reconstructive products; sports medicine, biologics, extremities, and trauma products; craniomaxillofacial and thoracic (CMFT) products; bone cement; surgical products; and an integrated suite of digital and robotic technologies powered by data analytics and artificial intelligence. Headquartered in Warsaw, Indiana, Zimmer Biomet partners with orthopedic surgeons, neurosurgeons, healthcare institutions, stocking distributors, and healthcare dealers across more than 100 countries to alleviate pain and improve the quality of life for patients worldwide.
Business Segments
Zimmer Biomet allocates resources and assesses performance across three regional operating and reportable segments:
- Americas: Comprises primarily the United States, along with Canada and Central and South American markets. In 2025, the Americas generated net sales of $5,144.6 million and segment operating profit of $2,645.7 million. The U.S. market accounted for approximately 95 percent of net sales in this region.
- EMEA (Europe, Middle East, and Africa): Covers European nations alongside the Middle East and Africa. Key markets include France, Germany, Italy, Spain, and the United Kingdom, which together accounted for approximately 50 percent of regional net sales. In 2025, the EMEA segment delivered net sales of $1,828.8 million and segment operating profit of $595.0 million.
- Asia Pacific: Encompasses key markets including Japan, China, Australia, New Zealand, South Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. Japan represents the largest market, accounting for approximately 50 percent of regional net sales. In 2025, the Asia Pacific segment recorded net sales of $1,258.1 million and segment operating profit of $446.0 million.
History and Evolution
Zimmer Biomet’s origins date back to 1927, when predecessor Zimmer Manufacturing Company was established in Warsaw, Indiana. In August 2001, the company was spun off from its former parent company to become an independent public corporation listed on the New York Stock Exchange. A major milestone took place in 2015 when Zimmer Holdings acquired LVB Acquisition, Inc., the parent entity of Biomet, Inc., leading to the combined entity adopting the name Zimmer Biomet Holdings, Inc. In March 2022, the company completed the tax-free spinoff of its dental and spine businesses into an independent public entity, ZimVie Inc., divesting its remaining retained interest in February 2023. Strategic expansion continued in 2025 with the acquisitions of Paragon 28, Inc. to enhance its extremities portfolio and Monogram Technologies Inc. to broaden its robotic and surgical planning capabilities.
Products and Services
Zimmer Biomet categorizes its global product portfolio into four key groups:
- Knees: Total knee replacement systems, partial unicompartmental solutions, and revision surgery implants, including femoral components, tibial trays, patellae, and articular surfaces.
- Hips: Total hip replacement and revision solutions replacing the femoral head and pelvic socket (acetabulum), utilizing cemented or press-fit porous ingrowth/ongrowth surfaces.
- S.E.T. (Sports Medicine, Extremities, Trauma, CMFT): Soft tissue repair systems, early joint intervention biologics, foot and ankle devices, upper extremities (shoulder, elbow, wrist) replacements, internal fixation trauma nail and plating systems, and craniomaxillofacial and thoracic implants.
- Technology & Data, Bone Cement, and Surgical: Encompasses the ZBEdge® Platform linking robotic and digital workflows, surgical navigation, artificial intelligence analytics, bone cements, mixing accessories, and specialized operating room capital products.
Brand Portfolio
The company maintains a broad portfolio of proprietary brands and trademarks across its surgical and implant lines:
- Knee Brands: Persona® Knee, Persona® OsseoTi® Keel Tibia, NexGen® Knee Implants, Vanguard® Knee, Oxford® Partial Knee, Persona® Revision SoluTion™ Femur, and ROSA® Knee with OptimiZe™.
- Hip Brands: Taperloc® Hip System, iTaperloc® Complete, Avenir Complete® Hip System, Z1® Femoral Hip System, Arcos® Modular Hip System, G7® Acetabular System, and iG7™ Hip System.
- Extremities, Trauma, Sports Medicine & Biologics Brands: JuggerKnot® Soft Anchor System, Gel-One® Cross-linked Hyaluronate (trademark of Seikagaku Corporation), Comprehensive® Shoulder, Natural Nail® System, SternaLock® System, and Gorilla® Ankle Fracture Plating System.
- Surgical, Robotics & Digital Technologies: ROSA® Robotic Solutions, ZBEdge® Platform, and OrthoGrid®.
Geographical Presence
Zimmer Biomet operates an extensive global manufacturing, research, and distribution footprint:
- Facilities & Real Estate: The company owns or leases approximately 300 facilities worldwide, with roughly half situated in the United States. Regional headquarters are located in Warsaw, Indiana (Global/Americas), Zug, Switzerland (EMEA), and Singapore (Asia Pacific).
- Manufacturing Footprint: Approximately 25 manufacturing facilities globally, primarily owned in the U.S. Major international manufacturing centers operate in Switzerland, Ireland, and China.
- Research & Development Centers: Primary R&D hubs are located in Warsaw, Indiana; Denver, Colorado; Jacksonville, Florida; Austin, Texas; Montreal, Quebec, Canada; Zug, Switzerland; and Beijing, China.
- Distribution Centers: Centralized distribution hubs are maintained in the U.S. and the Netherlands, supported by market-level local facilities across more than 45 countries.
Board of Directors and Leadership Team
Zimmer Biomet is governed by an experienced Board of Directors and executive management team:
- Board of Directors: Ivan Tornos (Chairman), Betsy J. Bernard, Michael J. Farrell, Robert A. Hagemann, Arthur J. Higgins, Maria Teresa Hilado, Syed Jafry, Sreelakshmi Kolli, Devdatt Kurdikar, and Louis A. Shapiro.
- Executive Management: Ivan Tornos (President and Chief Executive Officer), Suketu Upadhyay (EVP and Chief Financial Officer – Finance, Operations and Supply Chain), Kevin Thornal (Group President, Global Businesses and the Americas), Wilfred van Zuilen (Group President, EMEA), Sang Yi (Group President, Asia Pacific), Jehanzeb Noor (SVP, Chief Strategy, Business Development, Innovation and Transformation Officer), Chad Phipps (SVP, Chief Legal and Corporate Affairs Officer and Secretary), Paul Stellato (VP, Controller and Chief Accounting Officer), and Lori Winkler (SVP, Chief Human Resources Officer).
In 2025, Zimmer Biomet delivered. Despite tariff headwinds, the integration of three acquisitions and the early stages of a major evolution in our U.S. commercial model, we delivered solid sales growth, reflecting healthy end markets, strong product performance and disciplined execution across the enterprise.
Ivan Tornos, Chairman, President and Chief Executive Officer
Future Strategy
Zimmer Biomet’s operational and corporate roadmap centers on three foundational pillars:
- People & Culture: Accelerating executive decision-making and cross-enterprise prioritization via the newly established Operating Committee while investing in workforce training and leadership development.
- Operational Excellence: Transforming the commercial sales network, highlighted by converting significant portions of the U.S. sales force from independent sales agents to direct employees, establishing dedicated product category specialists, and building automated, sustainable manufacturing facilities.
- Innovation & Diversification: Scaling the “Magnificent Seven” product platforms, accelerating robotic surgery adoption through ROSA® and acquired Monogram technologies, expanding fast-growing extremities segments via Paragon 28, and bringing infection prevention innovations such as iodine-treated implants to international markets.
Key Strengths
Zimmer Biomet possesses several distinct competitive advantages across the orthopedic and medical device sector:
- Extensive Intellectual Property: Owns or licenses over 6,000 issued patents and pending patent applications worldwide.
- Integrated Digital & Robotic Ecosystem: The proprietary ZBEdge® platform and ROSA® robotic suites provide intraoperative precision and pre-to-post-operative data analytics.
- Global Market Reach & Consignment Model: Direct-to-care customer coverage where consigned inventory accounts for approximately 85 percent of consolidated net sales, securing deep hospital and surgeon integration.
- Scale in Established Care Channels: Global leadership in primary and revision knee and hip arthroplasty supported by a specialized workforce of approximately 17,000 employees worldwide.
Key Challenges and Risks
The company faces multiple operational, regulatory, and macroeconomic risks:
- Commercial Network Transformation: Multi-year transition of independent U.S. sales agents to direct employees introduces potential territory disruptions, turnover of key commercial personnel, and customer relationship friction.
- ERP System Integration Disruption: Deficiencies or delays in ongoing global enterprise resource planning software consolidations have historically led to shipping delays and order fulfillment challenges.
- Regulatory & Quality Compliance: Subject to stringent global regulations, including FDA Quality System Regulations, Form 483 observations, and the transitional compliance burdens of the European Union Medical Device Regulation (EU MDR).
- Governmental Pricing Pressure & Procurement Reforms: Downward price trends driven by hospital group purchasing organizations (GPOs), regional volume-based procurement (VBP) policies in China, and European payback laws.
- Indebtedness & Variable Interest Rates: Debt obligations totaling $7.5 billion at December 31, 2025 require substantial cash flow for servicing, with portions sensitive to benchmark interest rate fluctuations.
Conclusion and Strategic Outlook
Zimmer Biomet closed 2025 having expanded its footprint in high-growth foot and ankle and robotic orthopedic niches through the strategic acquisitions of Paragon 28 and Monogram Technologies. While the company navigates transition periods involving U.S. sales force conversion, global enterprise system upgrades, and persistent hospital pricing pressures, its strong innovation cycle and expanded portfolio position it to maintain durable long-term growth across musculoskeletal healthcare markets.
Official Site
Official Corporate Website: https://www.zimmerbiomet.com
Income Statement / Profit and loss
| Metric (in $ millions, except per share amounts) | 2025 | 2024 |
|---|---|---|
| Net Sales | 8,231.5 | 7,678.6 |
| Cost of products sold, excluding intangible asset amortization | 2,493.7 | 2,191.2 |
| Intangible asset amortization | 665.9 | 591.9 |
| Research and development | 458.5 | 437.4 |
| Selling, general and administrative | 3,257.2 | 2,929.8 |
| Restructuring and other cost reduction initiatives | 181.2 | 219.0 |
| Acquisition, integration, divestiture and related | 76.9 | 23.6 |
| Operating expenses | 7,133.4 | 6,392.9 |
| Operating Profit | 1,098.1 | 1,285.7 |
| Other income (expense), net | 25.5 | (31.1) |
| Interest expense, net | (292.8) | (218.0) |
| Earnings before income taxes | 830.8 | 1,036.6 |
| Provision for income taxes | 125.7 | 131.4 |
| Net Earnings | 705.1 | 905.2 |
| Less: Net (loss) earnings attributable to noncontrolling interest | (0.1) | 1.5 |
| Net Earnings of Zimmer Biomet Holdings, Inc. | 705.1 | 903.8 |
| Diluted Earnings Per Share ($) | 3.55 | 4.43 |
| Basic Earnings Per Share ($) | 3.56 | 4.45 |
Balance sheet
| Metric (in $ millions) | 2025 | 2024 | YoY Growth (%) |
|---|---|---|---|
| Cash and cash equivalents | 591.9 | 525.5 | +12.64% |
| Accounts receivable, less allowance for credit losses | 1,704.4 | 1,480.7 | +15.11% |
| Inventories | 2,286.4 | 2,235.3 | +2.29% |
| Prepaid expenses and other current assets | 537.3 | 430.1 | +24.92% |
| Total Current Assets | 5,119.9 | 4,671.5 | +9.60% |
| Property, plant and equipment, net | 2,207.1 | 2,048.8 | +7.73% |
| Goodwill | 9,947.1 | 8,951.1 | +11.13% |
| Intangible assets, net | 4,717.3 | 4,598.4 | +2.59% |
| Other assets | 1,100.3 | 1,095.5 | +0.44% |
| Total Assets | 23,091.7 | 21,365.3 | +8.08% |
| Accounts payable | 303.0 | 194.6 | +55.70% |
| Other current liabilities | 1,693.6 | 1,393.3 | +21.55% |
| Current portion of long-term debt | 587.1 | 863.0 | -31.97% |
| Total Current Liabilities | 2,583.7 | 2,450.9 | +5.42% |
| Deferred income taxes, net | 244.1 | 352.5 | -30.75% |
| Other long-term liabilities | 626.1 | 744.1 | -15.86% |
| Long-term debt | 6,932.0 | 5,341.6 | +29.77% |
| Total Liabilities | 10,386.0 | 8,889.1 | +16.84% |
| Common stock | 3.2 | 3.2 | 0.00% |
| Paid-in capital | 10,178.6 | 10,038.1 | +1.40% |
| Retained earnings | 11,611.0 | 11,095.3 | +4.65% |
| Accumulated other comprehensive loss | (205.7) | (262.8) | -21.73% |
| Treasury stock | (8,889.4) | (8,405.7) | +5.75% |
| Total Zimmer Biomet Holdings, Inc. stockholders’ equity | 12,697.7 | 12,468.1 | +1.84% |
| Noncontrolling interest | 8.1 | 8.1 | 0.00% |
| Total Stockholders’ Equity | 12,705.8 | 12,476.2 | +1.84% |
| Total Liabilities and Stockholders’ Equity | 23,091.7 | 21,365.3 | +8.08% |
Cash flow
| Metric (in $ millions) | 2025 | 2024 | YoY Growth (%) |
|---|---|---|---|
| Net cash provided by operating activities | 1,697.1 | 1,499.4 | +13.19% |
| Net cash used in investing activities | (1,975.7) | (888.1) | +122.46% |
| Net cash provided by (used in) financing activities | 326.0 | (484.5) | -32.71% |
| Effect of exchange rates on cash and cash equivalents | 19.0 | (17.1) | +11.11% |
| Increase in cash and cash equivalents | 66.4 | 109.7 | -39.47% |
| Cash and cash equivalents, beginning of year | 525.5 | 415.8 | +26.38% |
| Cash and cash equivalents, end of year | 591.9 | 525.5 | +12.64% |
Subsidiaries & Joint Ventures
- LVB Acquisition, Inc. (Wholly-owned subsidiary)
- Biomet, Inc. (Wholly-owned subsidiary)
- Zimmer, Inc. (Wholly-owned subsidiary)
- Paragon 28, Inc. (Wholly-owned subsidiary acquired on April 21, 2025)
- Monogram Technologies Inc. (Wholly-owned subsidiary acquired on October 7, 2025)
- OrthoGrid Systems, Inc. (Wholly-owned subsidiary acquired on October 11, 2024)
- V.I.M.S. Vidéo Interventionnelle Médicale Scientifique (Wholly-owned subsidiary acquired on April 29, 2024)
- Embody, Inc. (Wholly-owned subsidiary acquired on February 14, 2023)
- Zimmer GmbH (Operating entity, Switzerland)
- Zimmer Asia (HK) Limited (Operating entity, Hong Kong)
Other Investments & Holdings
- Strategic Partnership with Getinge (Capital products distribution for Ambulatory Surgery Centers)
- Investments in debt and equity securities (Fair value gains of $14.7 million in 2025; fair value losses of $42.1 million in 2024)
- Investments in partnerships (Recognized deferred tax asset of $52.6 million as of December 31, 2025)
Physical properties
- Warsaw, Indiana, United States: Corporate headquarters, principal research and development, and primary manufacturing facility for Knees, Hips, and S.E.T.
- Zug, Switzerland: EMEA regional headquarters and research and development facility.
- Singapore: Asia Pacific regional headquarters.
- Montreal, Quebec, Canada: Research and development facility.
- Denver, Colorado, United States: Research and development facility.
- Jacksonville, Florida, United States: Research and development facility.
- Austin, Texas, United States: Research and development facility.
- Beijing, China: Research and development and manufacturing facility.
- Global Manufacturing Network: Approximately 25 manufacturing locations worldwide, primarily owned in the United States and owned/leased internationally in Switzerland, Ireland, and China.
- Logistics & Distribution Facilities: Centralized distribution warehouses in the United States and the Netherlands, supplemented by local market facilities across more than 45 countries.
Investments and capital expenditure
- Additions to instruments: $300.5 million in 2025 ($240.3 million in 2024)
- Additions to other property, plant and equipment: $224.5 million in 2025 ($203.8 million in 2024)
- Research and development spend: $458.5 million in 2025 ($437.4 million in 2024)
- Acquisition of intangible assets: $52.4 million in 2025 ($153.0 million in 2024)
- Business combination investments, net of acquired cash: $1,393.2 million in 2025 ($276.3 million in 2024)
Shareholding pattern / Ownership
| Category | Shares | % Stake | Previous % Stake |
|---|---|---|---|
| Non-Affiliated Market Float (as of June 30, 2025) | 191,966,804 | 97.51% | 97.45% |
| Directors and Executive Officers as Affiliates (as of June 30, 2025) | 4,896,156 | 2.49% | 2.55% |
| Total Common Shares Outstanding (as of February 10, 2026) | 195,652,004 | 100.00% | 100.00% |
| Treasury Shares Held (as of December 31, 2025) | 123,200,000 | 27.88% | 27.16% |
Frequently Asked Questions
What is Zimmer Biomet’s primary business?
Zimmer Biomet designs, manufactures, and markets musculoskeletal healthcare products, including orthopedic implants for total joint reconstruction (knees and hips), sports medicine, biologics, foot and ankle, upper extremities, trauma, CMFT devices, bone cement, surgical supplies, and robotic/digital surgical navigation systems.
Where is Zimmer Biomet headquartered?
Zimmer Biomet’s global corporate headquarters is located at 345 East Main Street, Warsaw, Indiana 46580, United States.
On which stock exchanges are Zimmer Biomet shares traded?
The common stock of Zimmer Biomet Holdings, Inc. is publicly listed on the New York Stock Exchange and the SIX Swiss Exchange under the ticker symbol ZBH.
What acquisitions did Zimmer Biomet complete in 2025?
In 2025, Zimmer Biomet completed the acquisitions of Paragon 28, Inc., a foot and ankle orthopedic technology leader, and Monogram Technologies Inc., an orthopedic robotics developer.
How many employees does Zimmer Biomet have?
As of December 31, 2025, Zimmer Biomet employed approximately 17,000 team members worldwide, including about 2,000 dedicated to research and development and 6,000 in manufacturing.